选择性ErbB4激动剂JK07在心力衰竭中进行单次上升剂量研究,减少了射出分数
W H Wilson Tang1, Johannes Steiner2, Mahwash Kassi3
1Department of Cardiovascular Medicine, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.
JACC. Basic to translational science
|July 30, 2025
概括
试验中的药物JK07,一种选择性的ErbB4激动剂,在1期心力衰竭与减少喷射率 (HFrEF) 的试验中显示出前景. 早期的结果表明潜在的疗效和可接受的安全性,支持进一步研究心力衰竭患者.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 减少喷射分数 (HFrEF) 的心力衰竭仍然是一个重大的临床挑战.
- 准ErbB4通路为心血管疾病提供了潜在的治疗策略.
- 之前的研究表明神经素-1的效果延长,这表明ErbB4激动剂的潜在作用.
研究的目的:
- 为了评估JK07的安全性,耐受性,免疫性,药理动力学和探索性疗效,JK07是一种选择性的ErbB4激动剂.
- 评估JK07在心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者
- 为了在这个患者群体中确定JK07的安全剂量范围.
主要方法:
- 第一次在人身上,第一阶段,双盲,安慰剂控制的研究设计.
- 包括接受最佳目标导向医疗治疗的HFrEF患者.
- 用JK07在各种剂量水平上,包括0.09 mg/kg和0.27 mg/kg,与安慰剂对照.
主要成果:
- JK07在一般情况下是安全的,并且能很好地容忍0.09mg/kg.
- 在最高剂量 (0.27 mg/kg) 时,发现了增加不良事件的趋势.
- 探索性疗效显示左心室喷射分数的改善持续至输液后180天.
结论:
- 在HFrEF患者中,JK07在高达0.09毫克/千克的剂量下显示出一般有利的安全性.
- 观察到左心室喷射小部分的改善支持JK07的继续调查.
- 需要进一步的临床试验来证实JK07在心力衰竭治疗中的有效性和安全性.
更多相关视频
11:50High-frequency High-resolution Echocardiography: First Evidence on Non-invasive Repeated Measure of Myocardial Strain, Contractility, and Mitral Regurgitation in the Ischemia-reperfused Murine Heart
Published on: July 9, 2010
24.3K
08:31Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction
Published on: July 26, 2018
10.3K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
510
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
510
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
225
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
225
01:22Heart Failure Drugs: β-Blockers
435
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
435
01:26Heart Failure Drugs: Inotropic Agents
728
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
728
01:29Heart Failure II: Pathophysiology
44
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
44
01:22Heart Failure VI: Adjunct Therapies
28
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
28